Table 1.
Patient demographics and clinical characteristics of bladder cancer patients who received RARC
| Variable | All patients, N = 186 |
|---|---|
| Age, years, median (IQR) | 65 (32‐86) |
| Gender, n (%) | |
| Male | 157 (84.4) |
| Female | 29 (15.6) |
| BMI, kg/m2, median (IQR) | 24.7 (16‐45) |
| ASA score ≥3, n (%) | 26 (14.0) |
| No. of tumors, n (%) | |
| Solitary | 98 (52.7) |
| Multiple | 88 (47.3) |
| Hydronephrosis, n (%) | |
| Absent | 137 (73.7) |
| Unilateral | 34 (18.3) |
| Bilateral | 15 (8.1) |
| Clinical stage, n (%) | |
| ≤T1 | 39 (21.0) |
| T2 | 125 (67.2) |
| ≥T3 | 22 (11.8) |
| Pathological type, n (%) | |
| UC | 176 (94.6) |
| NUC | 10 (5.4) |
| Pathological grade, n (%) | |
| PUNLMP | 8 (4.3) |
| LGPUC | 62 (33.3) |
| HGPUC | 90 (48.4) |
| Fibrinogen, median (IQR) | 3.13 (1.22‐6.26) |
| NLR, median (IQR) | 2.62 (0.63‐34.5) |
| PLR, median (IQR) | 129.13 (34.55‐830.00) |
| LMR, median (IQR) | 3.33 (0.34‐8.28) |
| AGR, median (IQR) | 1.58 (0.73‐2.97) |
| PNI, median (IQR) | 47.0 (27.2‐63.1) |
Abbreviations: AGR, albumin‐globulin ratio; ASA, American Society of Anesthesiologists; BMI, body mass index; HGPUC, high‐grade papillary urothelial carcinoma; IQR, interquartile range; LGPUC, low‐grade papillary urothelial carcinoma; LMR, lymphocyte‐monocyte ratio; NLR, neutrophil‐lymphocyte ratio; NUC, non‐urothelial carcinoma; PLR, platelet‐lymphocyte ratio; PNI, prognostic nutritional index; PUNLMP, papillary urothelial neoplasm of low malignant potential; UC, urothelial carcinoma.